hist162493Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to telehealth.
hist162491Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to telehealth.
hist162489Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to name and address change, floor design, procedures for disciplinary proceedings, superseded references, and technical correction.
hist162487Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to requirements for class III permits for anesthesia.
hist162485Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to scheduling Crotonyl Fentanyl.
hist162483Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to scheduling Remimazolam.
hist162481Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to radiation protection requirements for radiation-producing machines and radioactive materials.
hist162479Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to scheduling Brorphine.
hist162477Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to service fund for people who are deaf, deafblind or hard of hearing.
hist162475Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to long-term care services and Medical Assistance fair hearing process.
hist162473Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to scheduling Serdexmethylphenidate.
hist162471Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to scheduling ten (10) fentanyl related substances.
hist162446Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to scheduling Alfaxalone.
hist162444Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to Excluding 6-beta-Naltrexol.
hist162442Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to scheduling Fospropofol.
hist162440Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to scheduling Embutramide.
hist162438Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to scheduling Perampanel.
hist162436Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to scheduling Lacosamide.
hist162434Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to transferring 1-phenylcyclohexylamine and 1-piperidinocyclohexanecarbonitrile, immediate precursors to phencyclidine, also known as PCP.
hist162432Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to telehealth.
hist162430Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to SeniorCare Prescription Drugs.
hist162428Referred to the joint committee for review of Administrative Rules, February 14, 2023. Relating to 4,4’-Dimethylaminorex.
hist162426Referred to the joint committee for review of Administrative Rules, February 14, 2023.